Dosage-dependent antifungal efficacy of V-echinocandin (LY303366) against experimental fluconazole-resistant oropharyngeal and esophageal candidiasis

Antimicrobial Agents and Chemotherapy

Volumn 45, Issue 2, 2001, Pages 471-479

  Petraitis, V ^a   Petraitiene, R ^a   Groll, A H ^a   Sein, T ^a   Schaufele, R L ^a   Lyman, C A ^a   Francesconi, A ^a   Bacher, J ^a   Piscitelli, S C ^a   Walsh, T J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; ANIDULAFUNGIN; FLUCONAZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CANDIDIASIS; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG TISSUE LEVEL; DUODENUM; ESOPHAGUS; FEMALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OROPHARYNX; PRIORITY JOURNAL; RABBIT; SALIVARY GLAND; STOMACH; THRUSH; TONGUE;

AMPHOTERICIN B; ANIMALS; ANTIBIOTICS, ANTIFUNGAL; ANTIFUNGAL AGENTS; CANDIDIASIS; CANDIDIASIS, ORAL; DRUG RESISTANCE, MICROBIAL; ESOPHAGEAL DISEASES; ESOPHAGUS; FEMALE; FLUCONAZOLE; IMMUNOSUPPRESSION; PEPTIDES, CYCLIC; PHARYNGEAL DISEASES; RABBITS; SALIVA;

EID: 0035139521     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.45.2.471-479.2001     Document Type: Article

References (35)

1. Population pharmacokinetics and renal function-sparing effects of amphotericin B colloidal dispersion in patients receiving bone marrow transplants
2. Fluconazole versus itraconazole for Candida esophagitis in acquired immunodeficiency syndrome
3. High-performance liquid chromatographic determination of amphotericin B in human serum
4. Esophageal candidiasis in pediatric acquired immunodeficiency syndrome: Clinical manifestations and risk factors
5. Antibiotics that inhibit fungal cell wall development
6. Semisynthetic chemical modification of the antifungal lipopeptide echinocandin B (ECB): Structure-activity studies of the lipophilic and geometric parameters of polyarylated acyl analogs of ECB
7. Antifungal dynamics of LY303366, an investigational echinocandin B analog, against Candida spp.
8. LY303366
9. The fungal cell wall as a drug target
10. Anti-Candida activity and toxicology of LY121019, a novel semisynthetic polypeptide antifungal antibiotic
11. Determination of fluconazole in human serum by solid-phase extraction and reversed-phase high-performance liquid chromatography
12. In vitro kill curves of a new semisynthetic echinocandin, LY-303366, against fluconazole-sensitive and -resistant Candida species
13. Evaluation of endpoints for antifungal susceptibility determinations with LY303366
14. Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans
15. New antifungal drug targets: A vision for future
16. Lipopeptide inhibitors of fungal glucan synthase
17. Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits
18. Cilofungin (LY121019) shows non-linear plasma pharmacokinetics and tissue penetration in rabbits
19. Safety, tolerance, and pharmacokinetics of fluconazole in children with neoplastic diseases
20. Interaction between fluconazole and amphotericin B in mice with systemic infection due to fluconazole-susceptible or -resistant strains of Candida albicans
21. A new therapeutic approach to Candida infections. A preliminary report
22. Antifungal activity of LY303366, a novel echinocandin B, in experimental disseminated candidiasis in rabbits
23. Antifungal efficacy, safety, and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits
24. In vitro susceptibilities of clinical yeast isolates to a new echinocandin derivative, LY303366, and other antifungal agents
25. Resistance of Candida species to fluconazole
26. Histopathological and immunohistochemical changes in gut-associated lymphoid tissues following treatment of rabbits with dexamethasone
27. In vitro activity of a new echinocandin, LY303366, compared with those of amphotericin B and fluconazole against clinical yeast isolates
28. Chronic silastic central venous catheterization for induction, maintenance, and support of persistent granulocytopenia in rabbits
29. Correlation between in vitro and in vivo antifungal activity in experimental fluconazole-resistant oropharyngeal and esophageal candidiasis
30. Dose-dependent pharmacokinetics of amphotericin B lipid complex in rabbits
31. The antifungal effects of the non-linear pharmacokinetics of cilofungin, a 1,3-β-glucan synthase inhibitor, during continuous vs. intermittent infusion of cilofungin in treatment of experimental disseminated candidiasis
32. Tissue homogenization with sterile reinforced polyethylene bags for quantitative culture of Candida albicans
33. Etiology of esophageal disease in human immunodeficiency virus-infected patients who fail antifungal therapy